About the Company
We do not have any company description for Tenaya Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last ...
A look at the shareholders of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) can tell us which group is most powerful. With 49% stake, individual investors possess the maximum shares in the company.
Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of ...
Tenaya Therapeutics, Inc. announces the appointments of Karah Parschauer to its Board of Directors and of Joanna Auch as SVP of People and Culture.
Tenaya Therapeutics Reports Q2 2025 Financial Results
Tenaya Therapeutics, Inc. ( ($TNYA) ) has released its Q2 earnings. Here is a breakdown of the information Tenaya Therapeutics, Inc. presented to ...
Tenaya Therapeutics Announces the Addition of Dr. June Lee to ... - Nasdaq
Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced changes ...
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most ...
For the full year 2024, Tenaya Therapeutics disclosed a net loss of $111.1 million, or $1.31 per share, compared to $124.08 million in 2023.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation ...
Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received a consensus rating of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports.
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You ...
Tenaya Therapeutics, Inc. (TNYA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug ...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative ...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 ...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 ...
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter ...
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Tenaya Therapeutics Launches Operations of New Genetic Medicines ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the ...
Similar Companies
Loading the latest forecasts...